IP Library Granted Patent US 10,035,826
Granted Patent B2
US 10,035,826 · App. 15/150,204 · Granted Jul 31, 2018

Proteins and nucleic acids from meningitis/sepsis-associated

Inventors: Vega Masignani (Siena, IT); Danilo Gomes Moriel (Monteriggioni, IT); Francesco Berlanda Scorza (Trento, IT); Nathalie Norais (Siena, IT); Maria Rita Fontana (Siena, IT); Mariagrazia Pizza (Siena, IT); Laura Serino (Monticiano, IT); Herve Tettelin (Gaithersburg, MD)
Assignees: GlaxoSmithKline Biologicals SA; J. Craig Venture Institute, Inc.
C07K14/245A61K39/0258C07K16/1232A61K39/00A61K2039/505A61K2039/523
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,035,826
App. No.
15/150,204
Granted
Jul 31, 2018
Kind
B2
Abstract

Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.

Claims (4)

1. An immunogenic composition comprising: (1) an immunologically effective amount of polypeptide comprising: (a) the amino acid sequence consisting of SEQ ID NO: 810, (b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 810; or (c) an amino acid sequence having at least 95% sequence identity to an amino acid sequence of (a) and including a fragment of at least 10 consecutive amino acids from an amino acid sequence of (a) and (2) an immunologically effective amount of adjuvant, wherein the immunologically effective amount of polypeptide is at least 1 μg/ml.

2. The immunogenic composition of claim 1 , wherein said fragment comprises at least one B-cell epitope of (a).

3. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

4. The immunogenic composition of claim 1 , wherein the composition is sterile.

Assignments (3)
CHANGE OF NAME Recorded Nov 8, 2018
From: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
To: GLAXOSMITHKLINE VACCINES S.R.L.
Reel/Frame 047485/0735 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: MASIGNANI, VEGA; MORIEL, DANILO GOMES; BERLANDA SCORZA, FRANCESCO; NORAIS, NATHALIE; FONTANA, MARIA RITA; PIZZA, MARIAGRAZIA; SERINO, LAURA
To: NOVARTIS VACCINES & DIAGNOSTICS SRL.
Reel/Frame 047485/0884 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2018
From: TETTELIN, HERVÉ
To: J. CRAIG VENTER INSTITUTE
Reel/Frame 047486/0370 →
Continuity (5)
Division 14293967 · Jun 2, 2014
Division 11884812
Provisional Application 60712720 · Aug 29, 2005
Provisional Application 60654632 · Feb 18, 2005
Related Publication 20160244489A1 · Aug 25, 2016